Biocon Secures USFDA Approval for Liraglutide Injection gSaxenda in Weight Management

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Biocon gets USFDA nod for Liraglutide injection gSaxenda for weight management

Tuesday, November 11, 2025 | Aavas Financiers, Atlanta Electricals, Atul Auto, Awfis Space Solutions, Bajaj Finserv, Balrampur Chini, Bharat Forge, Bikaji, Biocon, BLS International, Bosch, Borosil Renewables, Ciegall India, Cera Sanitaryware, CONCOR, Cosmo First, Dhampur Sugar, Ecos Mobility, Edelweiss, EID Parry, Emcure Pharma, EPL, ESAF SFB, Finolex Cables, Fortis Healthcare, GMR Power, Godrej Industries, Gokaldas Exports, GSFC, GSPL, Hindustan Copper, HT Media, Indo Count, IFCI, IOL Chemicals, JB Chemicals, Jupiter Wagons, Kolte Patil, Laxmi Dental, Manba Finance, MOIL, One Source, Orchid Pharma, Parag Milk, PC Jewellers, Rategain, RITES, RVNL, Subex, Surya Roshni, Suven Pharma, Tata Power, Texmaco Rail, Thermax, Torrent Power, TransRail Lighting, TVS Srichakra, Yatra Online, Zaggle,

C

CNBC TV18•24-02-2026, 22:30

Biocon gets USFDA nod for Liraglutide injection gSaxenda for weight management

•Biocon Ltd received USFDA approval for its Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda).
•Liraglutide is a drug-device combination for chronic weight management, used with a reduced-calorie diet and increased physical activity.
•GLP-1 receptor agonists are a fast-growing therapeutic class globally due to rising obesity and metabolic disorders.
•The US market opportunity for GLP-1 in weight loss was $127 million as per IQVIA MAT December 2025 data.
•Siddharth Mittal, CEO of Biocon, highlighted this approval as a defining milestone, validating the company's scientific depth and manufacturing platform.

Read Full Article on Cnbc in English

✦

More like this

✦

More like this

Biocon./Reuters

Biocon acquires Biocon Biosphere, Pharma for ₹315 Cr; Q3 net profit rises to ₹143.8 Cr

Fitch Upgrades Biocon Biologics Outlook to Positive, Affirms BB- Rating

Fitch Upgrades Biocon Biologics Outlook to Positive, Affirms BB- Rating

Zydus Lifesciences Secures USFDA Approval for Ammonium Lactate Cream

Zydus Lifesciences Secures USFDA Approval for Ammonium Lactate Cream

With the third quarter earnings season drawing to a close, there will be a beeline of companies reporting their quarterly results in the upcoming week. A combination of Nifty 50 companies, F&O stocks, and new listings as well, will be part of the list for the week. Here's a look at some of the major earnings that you should have your eyes on:

Biocon Biologics Targets FY27 Growth with New Approvals, GLP-1 Pipeline

Indoco Remedies Shares Soar 7% on USFDA Approval for Brivaracetam Oral Solution

Indoco Remedies Shares Soar 7% on USFDA Approval for Brivaracetam Oral Solution

FILE PHOTO: A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo

Eli Lilly stockpiles $1.5B weight-loss pill ahead of FDA decision